Autotransfusion Versus Transfusion in Cancer Surgery
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5,808
- 试验地点
- 1
- 主要终点
- number of annual uses of the intraoperative blood recovery system
研究概览
简要总结
Acute bleeding is one of the most frequent intraoperative adverse events and is burdened with a significant morbidity and mortality rate.
The only available treatment for severe exsanguination is homologous transfusion, but this is itself complicated by side effects.
Nevertheless, systems exist allowing the recovery, treatment and intraoperative reinjection of lost blood, thus limiting transfusions.
详细描述
Acute bleeding is one of the most frequent intraoperative adverse events and is burdened with a significant morbidity and mortality rate.
The only available treatment for severe exsanguination is homologous transfusion, but this is itself complicated by side effects (immunosuppression, increased rate of carcinological recurrence...).
Nevertheless, systems exist allowing the recovery, treatment and intraoperative reinjection of lost blood, thus limiting transfusions.
The aim of this work is to collect and analyze the estimated bleeding and the hemoglobin level of patients who underwent an intermediate or major operation in the general block of the Centre Léon Bérard in 2021 and who were transfused within 10 days of this operation.
In the first stage of data analysis, the investigators will collect data related to perioperative transfusion currently performed at the Centre Léon Bérard (year 2021).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Surgery at the Centre Léon Bérard in 2021
- •transfusion from the day of surgery to the 10th postoperative day
排除标准
- •Digestive endoscopy, interventional radiology, brachytherapy
- •Vascular access only
- •Patient refusal
结局指标
主要结局
number of annual uses of the intraoperative blood recovery system
时间窗: Up to 1 year
number of annual uses (at the Centre Léon Bérard in 2021) of the intraoperative blood recovery system in the indications validated by the French High Authority for Health
次要结局
- annual cost for the Centre Léon Bérard of the transfusion strategy.(Up to 1 year)